JPMorgan Chase & Co. Boosts Stock Position in Amdocs Limited $DOX

Key Points

• JPMorgan Chase & Co. increased its stake in Amdocs by 41.3% in Q3, adding 109,915 shares to hold 376,039 shares (about 0.35% of the company) worth roughly $30.85 million.
• Amdocs beat quarterly expectations, reporting $1.81 EPS vs. $1.75 expected and $1.16B revenue, and issued FY2026 guidance of $7.27–$7.55 in EPS (Q2 2026 guidance $1.73–$1.79).
• Dividend raised: the company increased its quarterly payout to $0.569 ($2.28 annualized), yielding about 3.5% with an ex-dividend date of March 31.

JPMorgan Chase & Co. grew its position in shares of Amdocs Limited (NASDAQ:DOX - Free Report) by 41.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 376,039 shares of the technology company's stock after purchasing an additional 109,915 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.35% of Amdocs worth $30,854,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Harbor Capital Advisors Inc. bought a new position in Amdocs during the third quarter valued at approximately $26,000. Root Financial Partners LLC bought a new stake in shares of Amdocs in the 3rd quarter worth approximately $26,000. WealthCollab LLC boosted its stake in shares of Amdocs by 94.5% in the 3rd quarter. WealthCollab LLC now owns 356 shares of the technology company's stock valued at $29,000 after purchasing an additional 173 shares in the last quarter. Atlantic Union Bankshares Corp bought a new position in shares of Amdocs during the 3rd quarter valued at $37,000. Finally, Abich Financial Wealth Management LLC bought a new position in shares of Amdocs during the 3rd quarter valued at $39,000. Hedge funds and other institutional investors own 92.02% of the company's stock.

Amdocs Trading Up 0.8%

NASDAQ DOX opened at $64.83 on Monday. The stock has a market cap of $7.00 billion, a P/E ratio of 12.54, a price-to-earnings-growth ratio of 1.15 and a beta of 0.42. Amdocs Limited has a fifty-two week low of $63.53 and a fifty-two week high of $95.41. The stock has a 50 day simple moving average of $73.35 and a two-hundred day simple moving average of $78.44. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.06 and a current ratio of 1.06.

Amdocs (NASDAQ:DOX - Get Free Report) last posted its earnings results on Tuesday, February 3rd. The technology company reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.75 by $0.06. The firm had revenue of $1.16 billion for the quarter, compared to analysts' expectations of $1.15 billion. Amdocs had a return on equity of 20.19% and a net margin of 12.47%.The business's revenue was up 4.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.66 earnings per share. Amdocs has set its Q2 2026 guidance at 1.730-1.790 EPS and its FY 2026 guidance at 7.270-7.550 EPS. On average, analysts forecast that Amdocs Limited will post 6.21 earnings per share for the current year.

Amdocs Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 24th. Stockholders of record on Tuesday, March 31st will be paid a dividend of $0.569 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.5%. The ex-dividend date of this dividend is Tuesday, March 31st. This is a positive change from Amdocs's previous quarterly dividend of $0.53. Amdocs's payout ratio is presently 43.91%.

Analyst Upgrades and Downgrades

DOX has been the subject of several recent research reports. Wall Street Zen downgraded shares of Amdocs from a "buy" rating to a "hold" rating in a research note on Saturday. Stifel Nicolaus reduced their price objective on Amdocs from $97.00 to $88.00 and set a "buy" rating on the stock in a research note on Wednesday, February 4th. Barclays decreased their price objective on Amdocs from $111.00 to $92.00 and set an "overweight" rating on the stock in a report on Wednesday, February 4th. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Amdocs in a report on Tuesday, January 27th. Three equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, Amdocs has a consensus rating of "Moderate Buy" and a consensus target price of $92.33.

About Amdocs

Amdocs NASDAQ: DOX is a global software and services provider specializing in solutions for communications, media and entertainment companies. The company designs, develops and integrates revenue management, customer experience and digital services platforms that enable service providers to launch and monetize new offerings, streamline operations and enhance subscriber engagement. Amdocs' product suite encompasses billing and order management, customer relationship management, digital commerce and network function virtualization, supported by professional services for implementation, integration and managed operations.

Founded in 1982 and structured as a separate public company in 1998, Amdocs has its corporate headquarters in Chesterfield, Missouri, and maintains major development centers in Ra'anana, Israel.

Want to see what other hedge funds are holding DOX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amdocs Limited (NASDAQ:DOX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.